



21 December 2005

Giaconda's management team welcomes appointment of new Assistant Company Secretary and Corporate Administrative Officer

Giaconda Limited (ASX: GIA), appointed Kirrilli Parker as Assistant Company Secretary on 19 December 2005 working with Giaconda's Company Secretary, Mr Tal Dauth.

Kirrilli was also appointed Corporate Administrative Officer on 17 November 2005. She will work with Rosa Surace, Chief Operating Officer supporting her with Giaconda's office management, corporate administration and financial management. This will include annual budget development and control, supervision of corporate governance legal services, accounting services and processes and company secretarial services and processes.

Kirrilli started in the biotechnology industry in the area of diagnostics over two years ago with Sienna Capital Limited after several years in the sports industry. At Sienna she held the position of Executive Officer reporting to the MD/CEO, being responsible for the corporate administration and assisting with the commercialisation of technology from the Ludwig Institute for Cancer Research. She completed a Bachelor of Science in 1997 at Macquarie University, worked for 5 years in the not-for-profit sector with the Sydney University Football Club rising to General Manager during the last 2 years and concurrently completed a Masters of Commerce at The University of Sydney. Kirrilli is in the final stages of completing the Diploma of Applied Corporate Governance through the Chartered Secretaries of Australia. Giaconda's board and management welcomes her and her extensive administrative, and biotechnology sector experience as part of the team to drive Giaconda to achieve its goals.

About Giaconda Limited

Giaconda Limited is a biotechnology company involved in developing and licensing innovative and cost effective medical therapies in the field of gastroenterology. Giaconda's products are targeted towards the treatment of serious conditions that are not adequately addressed by any existing therapy. In this way, Giaconda's products are intended to satisfy these significant unmet medical needs of the gastrointestinal market. The Giaconda portfolio consists of five products, all of which are novel combinations of known compounds. Giaconda has two lead products, Myoconda[®] for the treatment of Crohn's Disease and Heliconda[®] for the treatment of resistant *Helicobacter pylori* infection. Both of these products are ready for Phase III clinical trials, with a Phase IIIa trial already complete for Myoconda.

For more information, please visit www.giaconda.net.au

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

ISSUED FOR : **GIACONDA LIMITED**
FOR FURTHER INFORMATION : **MS ROSA SURACE, CHIEF OPERATING OFFICER, GIACONDA LIMITED**
TEL: (02) 9266 0440 (BUS): www.giaconda.net.au

GIACONDA LIMITED

Suite 1307, Level 13, 370 Pitt Street, Sydney NSW 2000 Phone: [612] 9266 0440 Fax: [612] 9266 0441

email: info@giaconda.net.au

www.giaconda.net.au